Home Tags CTLA-4

Tag: CTLA-4

HPAPI Lab at Abzena. Photo Courtesy: 2019 Abzena.

Addressing the Challenges of Bioconjugate Medicines

The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-, radionuclide-, immunomodulator- and check-point inhibitor-conjugates, can start to address the...

FDA Accepts Investigational New Drug Application for CTLA-4 Probody Therapeutic

Bristol-Myers Squibb has received acceptance of the Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for a CTLA-4-directed Probody™...

First of Two Planned Trials Combining Brentuximab Vedotin and Nivolumab Start...

Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...

Monoclonal Antibodies (mAbs), the “Magic Bullets” of Cancer Care, Are Now...

Monoclonal Antibodies (mAbs), once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way,...